BUZZ-MangoRx falls as Lilly sues firm over sale of copycat weight-loss drug

Reuters10-21 17:30

** Shares of telehealth company Mangoceuticals , also known as MangoRx, fall 4% to $2.43 before the bell

** Eli Lilly sues three medical spas and online vendors, including MangoRx, for selling products claiming to contain tirzepatide, the main ingredient in its popular weight-loss drug Zepbound

** Earlier this month, MangoRx launched its own brand called "Trim" - a compounded, oral dissolvable tirzepatide tablet

** Lilly said MangoRx was selling an oral version despite the lack of any study showing that formulation to be safe and effective

** MangoRx also sells "Slim", its oral compounded formulation of semaglutide, the active ingredient in Novo Nordisk's Wegovy

** MangoRx did not immediately respond to a request for comment

** As of last close, MGRX down nearly 42% YTD

(Reporting by Bhanvi Satija in Bengaluru)

((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment